Literature DB >> 11137588

An IgM anti-MBP Ab in a case of Waldenstrom's macroglobulinemia with polyneuropathy expressing an idiotype reactive with an MBP epitope immunodominant in MS and EAE.

B D Noerager1, T Inuzuka, J Kira, J E Blalock, J N Whitaker, F S Galin.   

Abstract

In a previously described case of Waldenstrom's Macroglobulinemia, complicated by polyneuropathy, the IgM/lambda monoclonal antibody (mAb) was highly reactive with myelin basic protein (MBP). Given our demonstration that V lambda x, a recently described murine lambda variable region gene product, can itself bind MBP as well as confer MBP reactivity to an Ab, the possibility of a shared idiotypy between murine V lambda x and this human IgM/lambda anti-MBP was investigated. We characterized the epitope specificity of the macroglobulinemia patient's MBP-reactive IgM/lambda using indirect ELISA procedures with MBP, a citrullinated isomer of MBP termed C8, or peptide fragments of MBP as the coating antigens and monospecific Ab to V lambda x as the secondary Ab. The patient's MBP-reactive IgM/lambda was recognized by Ab specific for V lambda x and, like murine mAb containing V lambda x bound human MBP but not MBP-C8 nor other common autoantigens such as DNA, thyroglobulin, or actin. The anti-MBP reactivity was selective for MBP peptide 90-170 and preferentially recognized MBP peptide 84-96. Thus, the patient's macroglobulin and perhaps certain other human Ab with a 'V lambda x idiotype' bind to MBP peptide residues 84-96, an immunodominant peptide in multiple sclerosis patients. Such binding may be involved in the pathogenesis of neural damage in patients with neuroimmunologic disorders related to plasma cell dyscrasias or autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137588     DOI: 10.1016/s0165-5728(00)00425-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

Review 1.  Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.

Authors:  Lei Yang; Dewei Tan; Hua Piao
Journal:  Neurochem Res       Date:  2016-04-21       Impact factor: 3.996

2.  Editing anti-DNA B cells by Vlambdax.

Authors:  Yijin Li; Yoram Louzoun; Martin Weigert
Journal:  J Exp Med       Date:  2004-02-02       Impact factor: 14.307

3.  Light chain editors of anti-DNA receptors in human B cells.

Authors:  Olga Kalinina; Yue Wang; Kevin Sia; Marko Radic; Pierre-André Cazenave; Martin Weigert
Journal:  J Exp Med       Date:  2014-01-27       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.